Showing 3261-3270 of 4063 results for "".
- Outlook Therapeutics Provides Update on Type A Meetings with FDA for Wet AMD Product Candidatehttps://modernod.com/news/outlook-therapeutics-provides-update-on-type-a-meetings-with-fda-for-wet-amd-product-candidate/2481959/Outlook Therapeutics announced that it has completed the requested Type A Meetings with the FDA to discuss the complete response letter (CRL) dated August 29, 2023 regarding the biologics license application (BLA) for ONS-5010, an investigational ophthalmi
- IRIS Registry-based Study Evaluates Side-Effect of Semaglutide Weight-Loss Drug on Diabetic Retinopathyhttps://modernod.com/news/iris-registry-based-study-evaluates-side-effect-of-semaglutide-weight-loss-drug-on-diabetic-retinopathy/2481947/According to the American Academy of Ophthalmology (AAO), new review of real-world data offers reassurance for the use of the diabetes drug semaglutide, which is popular for helping people lower their glucose levels and better manage their weight. At issue has been that a potential side effect of
- Adverum’s Ixo-Vec for Wet AMD Evaluated in 3-Year Data from OPTIC Extension Studyhttps://modernod.com/news/adverums-ixo-vec-for-wet-amd-evaluated-in-3-year-data-from-optic-extension-study/2481951/Adverum Biotechnologies announced updated data from the OPTIC extension study of patients with wet age-related macular degeneration (AMD) and a summary of previously announced aflibercept protein levels from the LUNA study were presented during the Retina Subspecialty Day at AAO 2023 in
- Ace Vision Group Names Rob Kissling, MD, as Chief Medical Officerhttps://modernod.com/news/ace-vision-group-names-rob-kissling-md-as-chief-medical-officer-1/2481938/Ace Vision Group announced that it has named Rob Kissling, MD, as Chief Medical Officer. Dr. Kissling has more than 20 years of experience integrating clinical development, medical strategy, and business planning to develop and commercialize devices and medicines for ophthalmology.
- Ocuphire Pharma Announces Appointment of George Magrath, MD, MS, as Chief Executive Officer and Directorhttps://modernod.com/news/ocuphire-pharma-announces-appointment-of-george-magrath-md-ms-as-chief-executive-officer-and-director/2481927/Ocuphire Pharma announced the appointment of George Magrath, MD, MS, as Chief Executive Officer and member of the Board of Directors, effective today. Dr. Magrath succeeds Rick Rodgers, Interim CEO and President since April 2023. Mr. Rodgers will remain on the company’s Board of Direct
- Samsung Bioepis' Byooviz Approved as Interchangeable with Lucentishttps://modernod.com/news/samsung-bioepis-byooviz-approved-as-interchangeable-with-lucentis/2481912/Samsung Bioepis annoounced that the FDA has approved the supplemental biologics license application (BLA) for Byooviz (ranibizumab-nuna) as a biosimilar product interchangeable with Lucentis (ranibizumab). The FDA originally approved Byooviz in September 2021 a
- Endogena Therapeutics Secures FDA Green Light to Initiate Trials for Geographic Atrophy Treatmenthttps://modernod.com/news/endogena-therapeutics-secures-fda-green-light-for-breakthrough-amd-treatment/2481909/Endogena Therapeutics announced that the FDA has granted clearance for Endogena's investigational new drug (IND) application, allowing the company to commence a first-in-human study in 2024 for its geographic atrophy drug cadidate EA 2351. This milestone marks the com
- Lighthouse Guild to Host Lectures on Ophthalmic Drug Approvals, Technological Innovations, and Advocacy for People with Vision Impairmenthttps://modernod.com/news/lighthouse-guild-to-host-lectures-on-ophthalmic-drug-approvals-technological-innovations-and-advocacy-for-people-with-vision-impairment/2481898/Lighthouse Guild will host three lectures on the latest advances in treatment, technology, and advocacy for people who are blind or have vision loss on Thursday, October 19, 2023, 12-1:30 pm ET, at their headquarters, 250 West 64th Street in Manhattan. Lectures:
- FDA Approves Orasis Pharmaceuticals' Presbyopia Eye Drop Qlosihttps://modernod.com/news/fda-approves-orasis-pharmaceuticals-presbyopia-eye-drop-qlosi/2481896/Orasis Pharmaceuticals announced that the FDA has approved Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. Qlosi is expected to be commercially available in the US in the first half of 2024. Qlosi is a p
- Optos Unveils New Retinal Imaging Technology at Euretinahttps://modernod.com/news/optos-unveils-new-retinal-imaging-technology-at-euretina/2481893/Optos announced advances to its ultra-widefield multimodal retinal imaging at its satellite symposia at the Euretina congress in Amsterdam. Optos’ devices capture ultra-widefield (UWFTM) high-resolution optomap images of 200 degress of the retina in a sing